Our technologies are designed to be better than cornea from human donor. We ensure quality of corneal endothelium. Often times, endothelial dysfunction occurs in cornea obtained from human donor; therefore, causing corneal graft failure. To further reduce graft failure, our cell collections provide immunological similarities. In high-risk individuals, mismatches of immunological profiles are also a major cause of endothelial dysfunction and graft failure.
In 2015, the European Commission has recently approved limbal stem cell product, setting a milestone to use cell replacement therapy to restore vision.